The efficacy of topical NSAIDs for anti-VEGF therapy for vitreomacular disease

The efficacy of topical NSAIDs for anti-VEGF therapy for vitreomacular disease - The efficacy of topical NSAID

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014929

Enrollment

200

Registered

2014-08-23

Start date

2014-08-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinal vein occlusion diabetic retinopathy age related macular degeneration

Interventions

Topical NSAID for 1 year follow up Topical artificial tear as placebo for 1 year follow up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Macular edema with diabetic retinopathy, retinal vein occlusion, or age-related macular degeneration. central macular thickness more than 400 mirometer. logMAR visual acuity between 0.5 and 1 treatment naive case senseitive to anti-VEGF therapy

Exclusion criteria

Exclusion criteria: macular ischemia ocular inflammation systemic disorder other than hypertension and hypercholesterolaemia

Design outcomes

Primary

Measure	Time frame
Progression of visual acuity Regression of macular thickness	—

Secondary

Measure	Time frame
frequecy of anti-VEGF treatment	—

Countries

Japan

Contacts

Public ContactKanako Yasuda

Tokyo Medical University Hachioji Medical Center Ophthalmology

kana6723@yahoo.co.jp0426655611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026